The core of our technology portfolio consists of an unique targeting peptide. This peptide is derived from an endogenous protein that circulates in our blood and has several remarkable qualities:
When mixed with polynucleotide drugs, it forms defined nanoparticles, which can be controlled in size according to an easily scalable process.
The outside of the nanoparticles is completely composed of peptide, which protects the polynucleotide drug from degradation and recognition by the (innate) immune system.
The peptide binds with high affinity to a specific (for IP-reasons undisclosed) receptor, allowing specific targeting of the nanoparticle to the glomerulus. Thereby we prevent drug delivery in any other organ than the kidney and as a consequence avoid many of the side-effects common in the current treatments.